United States: Silicone Implant Defendants Prevail On Fraudulent Joinder And Preemption

Offhand, we cannot think of opinions we have blogged on that pleased us more than today's cases, Jacob v. Mentor Worldwide, LLC, et al., 2019 WL 3500325 (C.D. Cal. Aug. 1, 2019) and Vieira v. Mentor Worldwide, LLC, et al., 2019 WL 3500331 (Aug. 1, 2019). The two decisions are virtually identical and come out the right way on issues important to drug and device defendants, such as snap removals, fraudulent joinder, and preemption. The decisions are well-reasoned, well-organized, and well-written All of that is encouraging and important. But the additional fact that delights us is that the author of the opinions is Judge Andre Birotte.

We have been an admirer of Andre Birotte for almost a quarter of a century. We were in the United States Attorney's Office in Los Angeles back in 1995, when Birotte came on board. He had formerly served as a deputy public defender, so he brought a useful perspective to the task. Right from the start, Birotte was a superstar AUSA. He was brilliant, hard-working, and had a marvelous sense of humor. It was evident that he was destined for higher things. It did not take long. Birotte was appointed by President Obama as the United States Attorney. Later, he became a federal judge. His accomplishments are impressive. Birotte was born to Haitian immigrants in Newark , New Jersey, not far from where we grew up. The last time we saw Birotte was at a dinner in honor of an AUSA colleague who died of ALS. It was an evening filled with stories, tears, and laughter. Not to put too fine a point on it, we think the world of Birotte. So, in addition to our defense-hackiness, please take into account our veneration of the Judge as we take a look at the Jacob and Vieira opinions.


The Jacob and Vieira cases were both filed in California state court on behalf of multiple plaintiffs alleging injuries from ruptured silicone breast implants. The plaintiffs sued multiple defendants, including the manufacturer, the raw material supplier, and a holding company. The holding company, like some of the plaintiffs, was a citizen of California. The causes of action included negligence, failure to warn, and manufacturing defect. The defendants removed the case to federal court and then moved to dismiss the complaints for failure to state a claim. The plaintiffs moved to remand the cases to state court.


The Jacob case involved a snap removal (that is, prior to service) by one of the defendants. As usual, the plaintiff resisted a literal interpretation of 28 U.S.C. section 1441(b)(2), which provides that a civil action "may not be removed if any of the parties in interest properly joined and served as defendants is a citizen of the State in which such action is brought." The Jacob case had been removed before any California defendant had been served, so the forum defendant rule of section 1441(b)(2) did not warrant remand. To be sure, there is some C.D. Cal. authority that waters down the availability of snap removals if there are "absurd or bizarre results." For example, in one prior case the defendants filed a notice of removal on diversity grounds before the Superior Court made the summons available to the plaintiff. In that case, it was impossible for the plaintiff to serve the defendants before removal. But nothing like that unusual situation existed in Jacob. It had not been impossible for the plaintiff in Jacob to serve the defendants. Thus, the Jacob court followed C.D. Cal. precedent, followed the plain text of section 1441(b)(2), and refused to remand the case on the basis of the forum defendant rule. (You can find our magnum opus on pre-service removal here.)

That did not end the subject of subject matter jurisdiction. In both the Jacob and Vieira cases, the court could not retain federal jurisdiction without deciding whether the California holding company had been fraudulently joined. If the holding company was legitimately in the case, there was no diversity jurisdiction, at least not with the California plaintiffs. (The court decided that the various plaintiffs had been properly joined. That is the one part of these decisions we do not adore.) Most of you reading this blog know that it is not easy for defendants to show fraudulent joinder. Nevertheless, demonstrating fraudulent joinder did turn out to be pretty easy in Jacob and Vieira. In a product liability action, the plaintiff must establish that the defendant produced, manufactured, sold, or was in some way responsible for the allegedly defective product. (Is that "some way responsible for" the basis for innovator liability in The Golden State? Grrrr. Do not get us started.) The holding company did not produce, manufacturer, or sell. It merely ... held. And it what it held was investments, not silicone breast implants. The holding company was not a proper defendant in these lawsuits. It was dismissed, and the cases stayed in front of an article III federal judge – and a very good one, at that.


The breast implants were class III medical devices that went through the rigorous pre-market approval (PMA) process. As such, they are covered by the express preemption provisions of the Medical Device Amendments (MDA). The plaintiffs, predictably, invoked the specious presumption against preemption. But Judge Birotte had read the SCOTUS Puerto Rico v. Franklin Cal. Tax-Free Trust case, and correctly ruled that there is no presumption against express preemption. The plain language of the MDA preempts state requirements that are "different from, or in addition to," federal requirements. One does not need a presumption to interpret that statement of Congressional intent; one needs only literacy. The plaintiff desperately argued that it was "difficult to believe that Congress would remove all means of judicial recourse for consumers injured by FDA approved devices." Judge Birotte's riposte was definitive: "Contrary to Plaintiffs' position, 'this is exactly what a pre-emption cause for medical devices does by its terms." (quoting Riegel). (We presumed to hold forth against the presumption against preemption here.)

Judge Birotte also ruled that the plaintiffs had not managed to thread the needle and state the dreaded parallel claim purportedly authorized by Riegel. As with many other circuits, the Ninth Circuit has recognized that there is a "narrow gap" through which a state-law claim must fit to escape preemption. The plaintiff must be suing for conduct that violates the federal Food, Drug, and Cosmetic Act (or else the claim would be preempted) but the plaintiff must not be suing because the conduct violates the FDCA (or else it would be preempted by Buckman). The plaintiffs in Jacob and Vieira claimed that the defendants violated federal and state law by failing to report adverse events to the FDA, but they cited no specific adverse events. The plaintiffs also claimed poor performance on post approval studies – but that results in a big so what. That is no violation of law. Finally, the plaintiffs claimed defective manufacturing that contravened federal regulations and state law, but the never identified the precise standards. In sum, the parallel violations were based on mere incantations, not allegations

Failure to Report

Cases from and within the Ninth Circuit suggest that the failure to warn claim's only hope for survival depended on a showing that if the defendants had properly reported adverse events to the FDA as required under federal law, that information would have reached the plaintiffs' doctors and thereby prevented the plaintiffs' injuries. Mind you, we think the theory is hogwash and should be preempted, but it doesn't much matter in the Jacob and Vieira cases, because the plaintiffs' allegations could not pass muster. The plaintiffs "have not explained how any purported failure to report the unspecified adverse events caused [their] injuries." Moreover, the plaintiffs did not "allege facts showing that the FDA would have exercised its discretion to include additional adverse events in its publicly-accessible adverse- event database." Nor did they allege that any of "their treating physicians even relied on information in the adverse event database making decisions."

Manufacturing Defect

Manufacturing defect claims are usually stinkers and that proved to be the case in Jacob and Vieira. The plaintiffs alleged that the implants "differed in some undefined way from the manufacturing and design specifications mandated by the FDA as part of the PMA." The plaintiffs merely alleged that the defendants violated unspecified "laws and regulations" or produced a "nonconforming" device. Such bloviations do not adequately establish violation of a federal requirement. They also do not establish that the alleged violations actually caused the alleged injuries. As Judge Birotte concluded, "[m]ore is needed."

Because the plaintiffs did not supply the more that was needed, and because it was clear that such "more" was not forthcoming, Judge Birotte dismissed the plaintiffs' claims with prejudice, "[a]s amendment would be futile."


We knew when we were in the U.S. Attorney's Office in the mid-90s that we were surrounded by a remarkable group of men and women. When we read opinions such as Judge Birotte's, or learn of Dan Collins's ascendancy to the Ninth Circuit, or see Representative Schiff on the cable news at night, or are treated to accounts in Law360 of former colleagues triumphing in front of juries and appellate panels, we count ourselves singularly blessed to have worked alongside such superb lawyers.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions